Sareum Holdings plc

(“Sareum” or “the Company”)

Additional disclosure concerning Michael Owen

Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.

It has come to Sareum’s attention that whilst his former directorship of BliNK Biomedical SAS (“BliNK”) was detailed in that announcement, his former directorship of BliNK’s subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.

For further information, please contact: